Audrey’s Life Science Meeting Picks for December-January 2011 Complimentary Service of AudreysNetwork.com (Dec. 5, 2011 Edition)

******************************************************************************* BioCentury TV Today, See the Webcast Sunday, Dec. 4, 2011 www.biocenturytv.com, Continuously available starting at 9:00 a.m. EDT

Topic: “The Doctor in the House”

Editor Steve Usdin is joined by Michael Burgess, Republican Congressional Representative from Texas Date: Sunday, Dec. 4, 2011 Watch the Broadcast Watch on the Web 8:30 - 9:00 a.m. EDT www.biocenturytv.com WUSA Channel 9 Continuously available in Washington, D.C. starting at 9:00 a.m. Topic Description

Representative Michael Burgess was an obstetrician for 25 years before being sent to Congress from Texas. Now vice-chair of the House subcommittee on health, he will be among the first lawmakers put his stamp on the must-pass user fee legislation for drugs and devices in 2012.

On Sunday, December 4, BioCentury This Week Washington Editor Steve Usdin and Rep. Burgess discuss why the conservative Texas Republican doesn't see eye to eye with the White House on healthcare reform, why he wants to limit FDA's oversight of lab-developed tests, and his efforts to relax financial conflict of interest restrictions on the agency's advisory committee members.

************************************************ Bio2Device Group, Tuesday Morning, Dec. 6, 2011

Topic: Title: "What's So Complicated About Medical Customer Support? - Views From Behind the Curtains" Panelists: John Jensen, Ron Bucher, Stacy Williams Date and Time: Tuesday, Dec. 6, 2011, 8:30- 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Park in Street and in NOVA and library parking lots across the street.

Topic Description Customer Support is a broad and complex functional area with its own unique life cycle and intricacies. It is also a differentiator affecting customer loyalty and overall revenue growth. This panel of Customer Support experts will make Customer Support be more tangible for you. They intend to make you aware of some of the not-so-obvious aspects of Customer Support, so that you can be more effective in your interactions with customers and with your Customer Support organization. As with other functional areas, Customer Support organizations are expected to operate with leaner resources while accomplishing greater results. In order for Customer Support to operate efficiently, it needs to be included and actively involved in Engineering, Manufacturing, Sales, Marketing, Finance, and Product Management processes. This brings about competing, and often conflicting priorities and decisions between departments. This panel will discuss how instituting a Customer Support mindset in design and manufacturing processes can eliminate many problems later on. You will walk away better equipped to make your company a stronger competitor in its market by having a better understanding of Customer Support as a strategic and competitive asset.

Panelist Bios John Jensen has spent over 30 years in customer service. Starting in 1981 as a Field Service Engineer for Picker International in it's X-ray division, John has worked many companies and areas of customer service. Some of those positions include, technical trainer, technical support, and installation coordinator. Aside from standard x-ray he has worked in cardiology, nuclear medicine, and CT technology. John also held the position of Customer Service / Account Manager with dpiX, LLC which provided Flat Panel Detectors to the Digital Radiology market.

Prior to joining the medical device industry with R2 Technology in 2006, Ron Bucher learned world class Customer Support competing directly with IBM at the top of the IT industry. His career grew from software engineer to North America VP and General Manager of Customer Support for the computer division of Siemens. Now his passion is bringing world class Customer Support to the medical industry. His medical device experience also includes Philips Healthcare and Boston Scientific.

Stacey Williams has spent over 20 years within the Medical Device Industry working for LifeScan (maker of home blood glucose monitoring devices). Stacey spent 17 of those years within the customer service organization and then held the role as Customer Service Manager until 2010. Stacey's passion is ensuring customers receive a positive experience by ensuring they are provided rapid, accurate and caring service.

*********************************************************

RAPS, Tuesday Evening, Dec. 6, 2011

Topic: “Social Media: A Regulatory Perspective” Speaker: Alan G. Minsk, JD, partner and practice leader, food and drug practice, Arnall Golden Gregory LLP Date and Time: Dec. 6, 2011, 5:30 – 8:30 pm 5:30 pm Registration Check-in 6:00–7:00 pm Dinner and Networking 7:00–8:30 pm Speaker Presentation and Q/A Period Location: Crowne Plaza, 1221 Chess Drive, Foster City, California 94404 Cost: $85; members, $70 Register at http://www.raps.org/publications-amp-resources/raps-store/product- detail.aspx?ProductID=2168014

Topic Description Join your regulatory colleagues from across the San Francisco Bay area for an evening of networking and an expert presentation entitled, “Social Media: A Regulatory Perspective.” This meeting is sponsored by the RAPS San Francisco Bay Area Chapter and is intended to promote knowledge advancement and facilitate networking among local regulatory professionals. With the increased use of social networking sites such as Twitter and Facebook, patients, healthcare providers and payers are interacting with brands and communities in new ways. As a regulatory professional, it is important to understand the implications of these new communication channels for your company. Noted food and drug attorney Alan Minsk will lead a lively discussion on this timely topic. At the conclusion of the program, you will: Understand regulatory framework and FDA scrutiny/guidance Have an awareness of regulatory and compliance safeguards to minimize risk

********************************************

Golden Gate Polymer Forum, Tuesday Evening, December 6, 2011

Topic: How to “Star” in Functional Self-Assembled Polymeric Materials Speaker: Joseph Sly, IBM Almaden Research Center Date and Time: Tuesday Evening, Dec. 6, 2011; 6:00 pm Schedule: 6:00 PM social hour 7:00 PM dinner 8:00 PM presentation Location: Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo Alto Restaurant's web page directions http://www.ichotelsgroup.com/crowneplaza/hotels/us/en/palo-alto/sfoca/hoteldetail/directions (not Mountain View site used in past)

Cost: Employed/postdocs: $30 advance registration, $35 regular registration Unemployed/retired/students: $15 advance registration, $20 regular registration Free if you attend just the lectures at 8:00 PM (but please let us know for headcount) After deadline: registration not guaranteed, so contact us late fee applies -- $40 regular/employed, $25 unemployed/student/retired GGPF Registration timelines and pricing policy. There is a discount for early registration in addition to a penalty for late registration.

See the table below. This is effective for all monthly dinner lectures. Registration may close earlier than the nominal deadline if capacity is reached. Employed/postdoc Student/unemployed/retired Early Registration $30 $15 Regular Registration Up to Registration Deadline $35 (30+5) $20 (15+5) After Deadline / Walk-in (Availability NOT $40 (30+10) $25 (15+10) guaranteed)

Register Discounted Early Registration Ends 5pm Monday, Nov. 28 --> Don't let Thanksgiving holidays cause you to miss the early registration discount. Please register on the web page www.GGPF.org Or, if necessary, contact: David Olmeijer, [email protected], 415-509-8948

You should receive confirmation of your registration; if not, please contact us again. Dinner Menu: No advance food choices to make this month (just choose "dinner" or "no dinner" for talk-only attendance) "Pacific Rim Buffet" with vegetarian options included.

Deadlines for registration: Advance registration discount ends 5pm Monday Nov. 28 Regular on-line registration ends 5pm Monday Dec. 5 Because we must pay the restaurant for the ordered meal, we must ask no-shows to pay for their reservation. However, penalty-free cancellations are allowed up until the deadline for reservations the day before the event.

PLEASE NOTE: we accept cash or checks, but are unable to accept payment by credit card at this time. You may pay at the door.

Topic Description Nanogel Star Polymers (uni-molecular, globular nanoparticles with a high number of polymer “arms” emanating from a nano-scale cross-linked polymer core) are an increasingly attractive class of polymer architecture for mediating/expressing structure-function relationships in materials science. They are also among the most synthetically demanding of polymeric nanostructures to develop, having long suffered from difficulties in characterization, reproducibility and control of key structural features such as particle size, arm number (polyvalency) and uniformity, all of which have provided a historical impediment to their general application. This talk will center on IBM’s recent program in developing convenient, scalable synthetic routes to highly uniform, size and chemically controlled nanogel star polymer architectures which are capable of tunable polyvalent functionality and programmable tandem-modal macromolecular self-assembly with other functional molecules and/or functional surfaces. This approach enables the formation of “dual-mode” composite nanoparticles with a range of functional “cargoes” which can be spontaneously formulated in a “plug and play” approach. Application areas for such materials, including image guided drug delivery vehicles (e.g., NIR photodynamic therapy delivery agents, dual mode cellular imaging agents, inorganic nanoshell templates for NIR photo-thermal ablation therapies) and functional surfaces (e.g., antibiotic surface coatings), will be highlighted

Speaker Bio Joseph Sly is a research scientist at IBM’s Almaden Research Center and for the past 6 years he has orchestrated a research unit, populated by IBM personnel and junior researchers borrowed from worldwide academia, working on “macromolecular” chemistry specializing in functional materials by self-assembly and light-activated functional composite polymeric nanoparticle architectures. Prior to joining IBM he was a post-doctoral fellow at Stanford University and a Marie Currie European Training Network Fellow at the University of Nijmegen (The Netherlands). Dr Sly obtained his Ph.D. at the University of Sydney (Australia) working on dendritic porphyrinoid light harvesting systems for organic photovoltaic applications.

*********************************************************** BIOMEDevice Conference, Tuesday and Wednesday, Dec. 6-7, 2011

Event: Medtech Conference and Exhibit Hall Date and Time: Tuesday and Wednesday, Dec. 6-7, 2011; 9:00 am – 4:00 pm Location: San Jose Convention Center Event Description This year's two day BIOMEDevice San Jose Conference will focus on the product design and development process for medical devices. Industry experts will address specific topics such as user needs and risk analysis, IP, regulations, 510(k), human factors, and supplier controls. Our mission is to ensure you leave the conference with new insights and practical information you can immediately apply to your job responsibilities. We hope you will join us! Cost: One day of conference-$599; two days-$795; exhibit hall is $45 or free if qualified by organization. Register for conference at http://canontradeshows.com/expo/biomed11/conference.html See full details at www.BIOMEDeviceSanJose.com *********************************************************** BioE2E, Wednesday Evening, Dec. 7, 2011 CANCELLED

Topic: “Effective Communications for Emerging Enterprises” *********************************************************

CACO Workshop, Monday, Dec. 12, 2011

Topic: “Human Mass Balance and Metabolite Profiling Studies: Fundamentals, Applications and Case Studie”s Speakers: Chandra Prakash (), Bernard Murray (Gilead), Evan Smith (), TBD () Date and Time: Monday, December 12, 2011, 8:45 am-5:00 pm Location: SF Bay Area: Foster City Crowne Plaza Event fee: Below cost of course materials for unemployed; For others, details available upon online login. Online registration and further details: http://www.caco-pbs.org Registration deadline: 12/11/2011 (it will close sooner if the seating cap is reached) About the Topic · Introduction (Chandra Prakash) 15 min · Design of radiolabeled ADME studies (Chandra Prakash) 60 min · QWBA & challenges in dosimetry calculation (Bernard Murray) 45 min · Methods for quantitation of radioactivity and metabolic profiling (Evan Smith) 60 min · AME Case studies for addressing DMPK issues (absorption, clearance mechanism and DDI evaluation) (Evan Smith) 60 min · Utility of human AME study to address MIST issues (Bernard Murray) 45 min · AMS for radiolabeled AME studies (Chandra Prakash) 30 min · Human AME study of large molecules (therapeutic protein, antibodies, antibody-drug conjugates, antisense nucleotides) (Genentech speaker) 45 min

******************************************************************************

CABS Seminar, Saturday Afternoon, Dec. 10, 2011

Topic: “Clinical Development and Beyond” Date and Time: Dec. 10, 2011, 1:00-4:30 pm 12:30 pm - 1:00 pm Registration and networking 1:00 pm - 1:40 pm Pharmacoeconomics and Pharmacogenomics in Clinical Trials Ullrich Schwertschlag, MD, Medical Consultant at Theravance and CMO at Attogen 1:40 - 2:20 pm Dose selection and PK/PD for Oncology Trials Soo-Peang Khor, Ph.D., Khor Pharmaceutical Consulting, formerly VP of Oncology at Geron 2:20 - 2:40 pm Coffee Break 2:40 - 3:20 pm Therapeutic Protein Drug Interactions with an Emphasis on Antibody Drug Conjugates Dan Lu, Ph.D., Associate Scientist, Department of Clinical pharmacology, Genentech 3:20 - 4:00 pm Evolving Models of Pharmaceutical Marketing and Sales Xi Wang, Ph.D., Clinical Science Consultant, Northwest District, Boehringer Ingelheim Inc. 4:00 - 5:00 pm Q&A and networking Register at http://www.cabsweb.org/CABSweb/feventslist.jsp?id=167 Registration Requirement: Online registration is strongly encouraged. Online registration: Onsite registration: Active members: $1 Non-members: $5 Active members: $5 Non-members: $10 Location: Syracuse Room, Crowne Plaza Hotel, 1221 Chess Dr., Foster City, CA 94404

Topic Description: The CABS Science Committee is proud to present the last of the 2011 workshop series, featuring rational clinical development and evolving business models for sales and marketing. Our featured speakers will share their experiences and case studies to illustrate recent developments in clinical research and post-approval sales and marketing.

*****************************************************************

FountainBlue's Life Science Entrepreneurs' Forum, Monday Evening, Dec. 12, 2011

Topic: “Robotics in MedTech” Facilitator Jack Moorman, LeVaunt, LLC Presenting Entrepreneur Robert Horst, Ph.D., Vice President of R&D & Cofounder, Tibion Presenting Entrepreneur Mike Ouren, Clinical Development Manager, Restoration Robotics Presenting Entrepreneur Bruce Richardson, CEO, Accel Biotech Presenting Entrepreneur Dr. Ramesh C. Trivedi, President, Calbiomed International, Inc. For more information and to register, visit http://www.svlifescience.com. Date & Time: Monday, December 12 from 5:30 - 7:30 p.m. Location: Bay Cafe Clubhouse, 1875 Embarcadero Rd, Palo Alto Pre-register by December 9 at noon: No-Cost for Members, $32 partners, $42 general Late and On-Site: $42 members, $52 non-members Members and Prospective Members can register at: http://fountainblue.shuttlepod.org/lifescience Non-Members and Partners can register using the PayPal link at: http://www.svlifescience.com To add questions, answers and resources on this and other FountainBlue topics, visit our crowdsourcing resource at Quora http://www.quora.com/Linda-Holroyd/questions Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please For more information and to register, visit http://www.svlifescience.com.

Topic Description Robotics in MedTech The accelerated pace of technology advancements is opening up new offerings in personalized medicine, in biomarker training, in Invitro diagnostics. This month we feature groundbreaking leaders to showcase advances and opportunities in this market and touch upon cultural and moral dilemmas which arise as these offerings gain traction. For more information and to register, visit http://www.svlifescience.com.

Speaker Bios Facilitator Jack Moorman, LeVaunt LLC Mr. Moorman has over 30 years of experience in Medical Device/Instrumentation, Nanotechnology and Semiconductor related businesses. The other 10 plus years has been in medical devices and biotech instrumentation. He has been the founder of seven companies and been the president of a publicly traded semiconductor equipment company, Nanometrics, Inc. Mr. Moorman has led multiple financing rounds. Mr. Moorman holds 13 issued US patents and is a member of the Intellectual Licensing Group. Mr. Moorman received a B.S. in Engineering from the University of Illinois and a Masters in Management from Stanford Business School.

Presenting Entrepreneur Robert Horst, Ph.D., Vice President of R&D & Cofounder, Tibion Robert Horst is the cofounder and Vice President of R&D at Tibion Corporation where he has been designing products for robotic therapy and mobility enhancement. He has more than 30 years of experience in electronics, systems architecture and fault-tolerant computing from his tenure at Hewlett Packard, Tandem Computers, Compaq, 3ware, and Network Appliance. As a consultant, he has worked with several startup companies and served as an expert witness in patent litigation. Dr. Horst is an IEEE Fellow and currently holds over 70 U.S. Patents. He received a BSEE from Bradley University, an MSEE from the University of Illinois and a PhD in Computer Science from the University of Illinois.

Presenting Entrepreneur Bruce Richardson, Founder and CEO, Accel Biotech Accel Biotech founder Bruce Richardson brings decades of innovative design and management experience to the organization. Bruce holds numerous patents and has worked in the medical device and biotechnology industry for over 20 years. He has earned a reputation for overcoming technical challenges and delivering products that succeed in the marketplace. At Accel Biotech he has defined strict requirements for technical and procedural excellence throughout the product development cycle.

Presenting Entrepreneur Ramesh Trivedi, President, CalbioMed, Inc. Ramesh Trivedi is currently President of CalbioMed, Inc. He was previously President & CEO at Integrated Surgical Systems, President and CEO at ROBODOC, a Curexo Technology Company, President &CEO at Vega Biotechnologies and President & CEO at DigiRad corp. He has done post- doctoral research in Chemical Engineering at Eidgenössische Technische Hochschule Zürich, received his PhD in Chemical Engineering from Lehigh University and his MBA in Business from Pepperdine University.

****************************************************************

Bio2Device Group, Tuesday Evening, Dec. 13, 2011

Topic: “Issues and Challenges Confronting Innovation” Speaker: Gail Maderis, President and CEO of BayBio Date and Time: Tuesday Evening, Dec. 13, 2011, 6:00-9:00 pm Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins

Topic Description Many consider the 21st Century to be the age of biology, positively affecting medicine, materials and processes. Much of the discovery has occurred in the Bay Area and will continue to do so with the appropriate support from the life sciences community. BayBio President and CEO Gail Maderis will provide insights into the political climate, its impact on our industry, and engage the Bio2Device community in real action for positive activism.

Speaker Bio Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to- peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis practiced management and strategy consulting with Bain & Co. She serves on the boards of BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. She received a BS in business from the UC Berkeley and an MBA from Harvard Business School.

*******************************************************

San Jose Biocenter, Tuesday Morning, Dec. 13, 2011

Topic: “Building a Financial Foundation –A Blueprint for Taking the Right First Steps” Speakers: Jeff Burkland, CEO (Part-Time CFO for Start-Ups), Burkland Associates Justin Roberts, Managing Director, BayPoint Benefits Brian Hassan, Managing Director, BayPoint Benefits Date and Time: December 13, 9:00am-10:30am Location: San Jose BioCenter, 5941 Optical Court, Second Floor, San Jose, CA 95138 $10 discount with registration at Register here: http://bffblue.eventbrite.com/?discount=AudeP

Topic Description With increased pressure to deliver value efficiently and effectively, startups need all the help they can get. Accurate, comprehensive operational management from the start is a crucial first step to the success of any business. Join us for a one hour interactive session on how you can best manage your operations resulting in maximum time spent on value creation and minimum time spent on developing and maintaining back-end policies, procedures and operational infrastructure.

In this session, you will learn: · Tricks & tips in finance, accounting, HR, employee benefits and more · Recommendations for leveraging desktop and cloud-based technology solutions such as Xero, inDinero, ADT, Expensify, Zuora, Coupa, and more · Outsourcing vs. In-House Operations Who Should Attend · Founders / Entrepreneurs · Newly founded corporations who find themselves overwhelmed with operational requirements · Rapidly growing start-up companies who can benefit from the part-time assistance and financial advice of senior level financial executives. · A small business requiring short-term support such as budget planning, audit preparation, finding office space, creation of benefit & incentive programs, or preparation for lay-offs · A foreign company establishing an office in the U.S.

***************************************************************

East Bay AWIS, Tuesday Evening, Dec. 13, 2011

Event: Please join us for the East Bay AWIS December Networking Social! Date and Time: Tuesday, December 13th, 2011; 6:30 pm – 8:30 pm Location: Pyramid Breweries, 901 Gilman Street, Berkeley, CA 94710 COST: FREE (Cash Bar) RSVP Here: http://linkd.in/s94zqf Directions: www.pyramidbrew.com/alehouses/berkeley Everyone is welcome, including non-scientists and men. If you are not an AWIS member yet, please join us! ***************************************************** Patheon Free Seminar in San Diego, Tuesday, Dec. 13, 2011

Topic: ”Moving from Molecule to Clinical Trial — Overcoming Challenges in the Early Development of Small Molecules” Date and Time: Tuesday, Dec. 13, 2011, 8:30 am – 2:00 pm Location: Hyatt Regency La Jolla, 3777 La Jolla Village Dr, San Diego, CA 92122 Seating is limited so RSVP asap RSVP: [email protected] See details including full agenda at http://www.patheon.com/Marketing/morningseminar/index.html..

Invitation Our team of expert pharmaceutical scientists is pleased to invite you to a complimentary morning seminar on Moving from Molecule to Clinical Trial — Overcoming Challenges in the Early Development of Small Molecules. The seminar will be held on Tuesday, December 13th at the Hyatt Regency La Jolla in San Diego. Topic Description Have you ever been looking to file an IND for your discovery compound and wondered “What do I have to do?” or heard about a molecule that failed to progress to clinical trials due to solubility issues? If so, then this seminar is for you. Patheon is proud to bring together four scientific leaders who, in a complimentary half-day seminar, will help you navigate through regulatory obstacles, give you tips for getting your molecule to clinical trials more efficiently, and provide practical case studies that demonstrate how other molecules have successfully moved to clinic.

As the global leader in Pharmaceutical Development Services, Patheon is committed to providing effective science-based learning opportunities for local professionals. Through this event, you will get the chance to network, meet with scientists, and learn from presentations with solutions to the challenges you currently or may face in the near future. Breakfast and lunch will be served.

Speaker Bios Leah Appel, Ph.D. has over 20 years experience in the , with extensive experience developing drug delivery technology and products. She has applied her expertise over the entire range of drug product development, both tailoring novel delivery technologies for clinical applications and commercializing products using drug delivery technologies. She is an inventor on over 35 drug delivery patents and patent applications. Her primary area of expertise is in oral solid dosage forms including controlled release and delivery of poorly soluble compounds. Leah obtained her B.S. in Chemical Engineering from UCLA in 1982, and her Ph.D. in Pharmaceutics from the University of Utah in 1988. Prior to founding Green Ridge Consulting in 2007, she worked for 10 years at Bend Research, Inc. as the Director of Controlled Release, and for 7 years at INTERx (a division of Merck) developing controlled release technologies. John McCarty has held R&D management positions at Key Pharmaceuticals, Schering Plough, and Pharmavene (acquired by Shire Pharmaceuticals) and is the founder of the international consulting firm Pharmaceutical Productions. John is known for his broad expertise in the development of all major dosage forms and is a contributor to industrial publications such as Tablet and Capsules and American Pharmaceutical Review. He is an inventor on numerous US and foreign patents. Until just recently he held the position of VP for Formulation Sciences and Drug Delivery at Azopharma Product Development Group. He earned Bachelors degrees in Microbiology and Chemistry from Florida Atlantic University in Boca Raton, FL.

Anil Kane, Ph.D., MBA, is presently the Senior Director, Pharmaceutical Technical Affairs, North America in the Pharmaceutical Development Services Group of Patheon Inc. He received his Bachelors, Masters and Ph.D. degrees from the University of Bombay, India and served as a post doctoral fellow at the School of Pharmacy at University of Cincinnati, Ohio. Dr. Kane has experience in the Pharmaceutical Development field for over 22 years, during which time he worked for Ciba Geigy Ltd. and subsequently Novartis. He has extensive knowledge of the entire drug development process, having been involved in taking molecules from early stage development to scale up, technical transfers between various manufacturing sites around the world and drug life cycle management. In his current role as Senior Director, Dr. Kane is leading a talented group of scientists in the development of novel lead compounds in this drug delivery area from early phase product development, clinical manufacturing and tech transfers for commercialization.

Gail L. Strong, Ph.D. has 20 years of pharmaceutical development experience. She spent 11 years at /Pharmacia/Pfizer focused on the drug discovery development interface in the pharmaceutics department, eventually as Director of Pharmaceutics for the three U.S. sites. She then joined Theravance as Director of Solid Forms. At Theravance she led the GI-motility team from early development through a successful Phase 2 proof of concept clinical study. In 2011 she joined Patheon as Senior Director of the South San Francisco Early Development lab. She received a B.S. in Chemical Engineering from Colorado State University, a M.S. in Chemical Engineering from the University of Arizona and a Ph.D. in Pharmaceutics from the University of Arizona and a Ph.D. in Pharmaceutics from the University of Michigan. *************************************************************

San Jose BioCenter, Meet With Abbott, Wednesday, Dec. 14, 2011

Event: Meet with Abbott Speakers: -Dr. Don Halbert, Division VP Abbott Bioresearch, Redwood City, Abbott -Dr. Neela Patel, Director ,External Research, West Coast, Abbott -Dr. Jeff Huff, Director, New Technology Assessment, Diagnostics, Abbott (tentative) Additional Abbott Attendees Include: -Murali Gopalakrishnan, Head, Global External Research -Bill Kohlbrenner, Director, Global External Research -Chuck Kunsch, Director, Global External Research (Immunology, Biologics) -Dieter Ziegler, Director, Global External Research (Neuroscience, Renal) -Daryl Sauer, Snr Group Leader, Global External Research (Enabling Technologies) -Nicole Walker, Abbott Bioventures Date and Time: Wednesday, Dec. 14, 2011, 9:30 am Registration & 9:30 AM - 10:00 AM Networking Presentation & 10:00 AM - 11:00 AM Q&A 11:00 AM - 11:30 PM BioCenter Tour Lunch & 11:30 PM - 12:00 PM Networking One-on-one 12:00 PM – 5:00 PM Meetings

Location: The San Jose BioCenter, 5941 Optical Court, Second Floor, San Jose, CA 95138 It is FREE to apply for a one-on-one meeting with Abbott. To apply, please send you executive summary to [email protected]. Application Deadline: November 11, 2011 Cost & Registration: PRESENTATION ONLY • Regular Price: $40 • Partners' Network: $30 • BioCenter Members: Free **Includes: Presentation & Q&A session + lunch ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! ONE-ON-ONE MEETINGS • APPLICATION: FREE • Regular Price: $175 • Partners' Network: $150 • BioCenter Members: Free **Includes: Presentation & Q&A session + lunch + one-on-one meeting (upon invitation). Register with special code for my network at Register Here: http://meetabbott.eventbrite.com/?discount=AudeP

Event Description Emerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the BioCenter "Meet with" Series, we provide emerging companies with greater access to partnering and/or financing opportunities. In this session, senior members from Abbott's team will talk to potential partners or licensees to first explain what they are looking for in collaborations, particularly, to enable preclinical drug discovery (emerging targets/biology, technologies and early stage compounds/antibodies) and diagnostics. After the presentation, each pre-approved company will be granted a private meeting with individuals from The Abbott Team. This is a great opportunity to showcase your technology and receive feedback regarding a possible partnership with Abbott. Abbott’s Areas of Interest: Preclinical Pharmaceutical Interests  Immunology (rheumatoid arthritis, osteoarthritis)  Neuroscience (schizophrenia, neurodegenerative diseases)  Pain (pain associated osteoarthritis, post-operative, neuropathic states and cancer)  Oncology (novel targets and mechanisms described in brochure)  Renal Diseases (diabetic nephropathy and chronic kidney disease)  Biologics  Enabling Drug Discovery Technologies and Drug Delivery approaches Diagnostics Interests  Next Generation Sequencing Technology  Nucleic Acid Sample Preparation Technology  Microfluidics (including immunodiagnostics, Point of Care, Hematology and molecular diagnostic applications)  Label Free detection based BioSensors for nucleic acid and immunoassay applications *************************************************************************** KPMG/Stanford School of Medicine Career Center, Wednesday Noon, Dec. 14, 2011

Topic: “KPMG Presents China's Pharmaceutical Industry - Poised for the Giant Leap” Speakers: David Blumberg, Advisory Partner in Charge of Global Pharmaceuticals & Life Sciences and Brian Wilson, Advisory Director, US-China Practice Leader for the Midwest Time and Date: Wednesday, December 14, 2011; 12:00noon -1:00pm Location: Li Ka Shing, 291 Campus Drive, Stanford University Sponsored by: School of Medicine Career Center RSVP Required: Send email to [email protected] Questions? [email protected]

Topic Description China is focused on transforming its economy from one that has been focused on double-digit GDP growth, exports, and serving as a low-cost manufacturing and labor base for the past three decades to one focused on sustainable growth, domestic consumption, and increasing its place in the value chain through technological superiority and indigenous innovation. Indeed, China stands at the cusp of a modern society, increasingly affluent and with a growing urban population demanding better services and quality of life. The government is also aware of the need to undertake a systemic overhaul of social, economic and financial structures for a more balanced society. Key components of this new agenda are an efficient pharmaceutical value chain and cultivating and leveraging indigenous innovation. In 2009, China launched an aggressive healthcare reform plan aimed at bringing all its citizens under basic medical coverage, modernizing health infrastructure and delivery, and overhauling the pharmaceutical industry. China’s 12th Five Year plan focuses on achieving this through continuous reform and policy incentives. Two main focus areas are the consolidation of the pharmaceutical distribution sector and biotechnology. China hopes to streamline and integrate its drug distribution and bring pharmaceutical production and sales closer together to reduce medicine prices; and biotechnology has been singled out as one of the seven ‘strategic emerging industries’. More investment in this biotech sector in particular can help resolve health problems associated with China’s rapidly ageing society, and we can expect the government to support innovative biotech products, high-end medical devices, and patented medicines. In this session, you will hear from KPMG’s experts on the pharmaceutical and biotechnology sectors in China. They will discuss the China market place, the government’s ambitions, how its long-term strategic goals in the pharmaceutical and biotechnology sectors will impact companies operating globally, and the trends that are impacting and will continue to steer the development of these sectors in China.

Speaker Bios David Blumberg leads KPMG’s Global Pharmaceuticals and Life Sciences Advisory practice. David has over 20 years of experience advising clients on a broad range of strategic, operational, information technology, and regulatory topics. He has worked across the life sciences continuum for over 18 years with experience in large global pharmaceuticals, specialty pharmaceuticals, generic pharmaceuticals, biotech, medical device, medical products, and diagnostics.

Brian Wilson is a Director with KPMG’s Advisory Services practice with more than 14 years of management advisory and business experience. He recently returned to KPMG US after spending 3 years with KPMG China where he led KPMG’s anti-bribery and corruption services for the Asia Pacific region while based in Shanghai. Brian worked closely with US and China partners in the Corporate Finance, Valuations, Transactions Services, International Tax, Supply Chain Management, Risk and Compliance, IT Advisory and Integration service lines to provide comprehensive solutions to clients to help them operate profitability and ethically in China and Hong Kong. Brian is currently focused on assisting US and Chinese companies with cross-border transactions and activities including market entry and expansion, US regulatory compliance, cross-border investigations and litigation, and forensic technology services. Similar to when he was in China, he focuses on helping companies with finding comprehensive solutions to their US and China needs and is a member of our Global China Practice and Investigations Services Network. Contact Information School of Medicine Career Center Phone: 650-721-1893 [email protected]

********************************************************************* BioScience Forum, Wednesday Night, Dec. 14, 2011

Topic: "Recent Trends in Mergers and Acquisitions in the Life Sciences Industry" Speaker: David Low, Managing Director and Co-Head of North American Life Sciences Lazard Capital Markets Date and Time: Wednesday, Dec. 14, 2011 6:00 PM - 9:00 PM Agenda 6:00 pm - 7 pm networking 7:00 pm - 8 pm dinner 8:00 pm - 9 pm presentation Location: The Holiday Inn, 275 S. Airport Blvd., South San Francisco, CA 94080 Register at https://www.cvent.com/events/bioscience-forum-david-low-managing-director-lazard- capital-markets/registration-316cfa269923426ab687388ae9be531e.aspx?i=e4ed0f89-115d-4a7f- 9b16-841f5738d2e9 Or go to http://biosf.org/ and find registration button at bottom of page Event Registration ($3 service fee will apply)

General Pre-Registration $45.00 General On-Site Registration $55.00 Student Pre-Registration $35.00 Student On-Site Registration $45.00 Pre-Registration ends Monday, Dec. 12, at 9 pm Cash or check accepted on the day of the event Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum 1442A Walnut Street, #308 Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, Dec. 8th If paying with check, do not complete online registration with Cvent

Topic Description Many large pharmaceutical and biotech companies remain cautious about structuring M&A deals at a time when their importance for the viability and success of the industry is only increasing. More and more deals tend to have contingencies for the buyer to help mitigate the risks involved in an M&A or a licensing transaction. How are these complex deals negotiated and structured? What are the key elements becoming standard in these transactions, many of which have long-term impact on the employees and shareholders of the affected organizations?

David, who has completed some of the biggest Bay Area life sciences M&A deals, will provide unique insights on the creation, management and future of these industry deals.

Speaker Bio David Low joined Lazard's Life Sciences Group in 2002 as a Managing Director based in San Francisco. Mr. Low has had a long career in Biotech M&A, advising on transactions including Roche’s restructuring of its Genentech ownership (1995 and 1999/2000), Johnson & Johnson’s acquisition of Centocor (1999) and Gilead’s acquisition of Myogen (2006), and Onyx Pharmaceuticals’ acquisition of Proteolix (2009) among others. On the financing side, Mr. Low has extensive experience with debt and equity, convertibles, R&D financings, private placements and royalty transactions for biotech companies.

************************************************************ San Jose BioCenter, Thursday, Dec. 15, 2011

Topic: “7th Annual Trends in Financing – The CEO Perspective” Speakers: • Peter Hirth, CEO - Plexxikon • Anand Mehra, Partner - Sofinnova Ventures • Peter Thompson, Co-Founder - Cleave BioSciences; Venture Partner, Orbimed Advisors • Guy Miller, CEO - Edison Pharmaceuticals • Jim Cornett, COO - Oxford BioTherapuetics - Invited • Scott Iyama, [Lead Facilitator] Partner - Orrick, Herrington & Sutcliffe, LLP Date and Time: December 15, 3:00 pm – 6:30 pm Agenda 3:00 PM - 3:30 PM Registration and Networking 3:30 PM - 5:00 PM Industry Panel 5:00 PM - 6:30 PM Holiday Celebration Networking Reception Location: Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road, Building 1100, Menlo Park, CA 94025-1015 Cost & Registration: • Regular Price: $60 • Partners' Network: $50 • Meet with Alumni: $35 • BioCenter Members: Free (please RSVP to [email protected]) • On-site Registration: add $10 to the above Use special code for discount for my network Register here: http://decbiocenter.eventbrite.com/?discount=AudeP

Topic Description Steady capital is a must for all companies. The first step in funding is knowing where to look. Join experts from the investment world at our annual “Trends in Financing Investor Panel & Holiday Celebration” to understand the types of financing that are occurring in your industry today - including topics such as who is getting funding while the world faces complex financial challenges - and what is new and to expect for 2011. Steady capital is a must for all companies. The first step in funding is knowing where to look. Join experts from the investment world at our annual "Trends in Financing Investor Panel & Holiday Celebration" to understand the types of financing that are occurring in your industry today - including topics such as who is getting funding while the world faces complex financial challenges - and what is new and to expect for 2012.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Holiday Celebration Networking Reception. ********************************************* PA AWIS, Thursday, December 15, 2011

Event: December Chapter Meeting: It's All About Networking Speakers: Alycia Shilton-Lloyd Ph.D., Jessica Bessler Ph.D., Cathleen Brdlik Ph.D. Our Panelists will discuss how their efforts and strategies have worked for them. Date and Time: Thursday, December 15, 2011 7-9 PM Location: Xerox PARC Auditorium, 3333 Coyote Hill Rd. Palo Alto, CA Cost: $5 Students/Members; $10 Others RSVP: http://bit.ly/tfjmJZ Flyer: http://pa-awis.org/flyers/AWIS_Flyer_December2011.pdf

************************************************* Bio2Device Group wishes you Happy Holidays on Tuesdays, Dec. 20 and 27, 2011

********************************************** San Jose BioCenter, Tuesday Lunchtime, January, 2012 Date to be selected

Topic: “All About Science-The Road to Biologic IND” (Originally scheduled for Dec. 6) Date and Time: January, 2012, 12:00pm-2:00pm Location: San Jose BioCenter, 5941 Optical Court, Second Floor, San Jose, CA 95138 $10 discount with this registration code Register here: http://lllind.eventbrite.com/?discount=AudeP

Topic Description Whether your goal is to develop your pipeline through commercial launch, or partner as early as possible, submitting an IND is a critical early milestone. Even with big pharma and VC firms competing for the most promising compounds, the bar is still quite high and startups are expected to demonstrate a solid plan for achieving IND acceptance to be taken seriously.

************************************************************* Bio2Device Group, Tuesday Morning, Feb. 28, 2012

Topic: “Developing Innovative Biotherapeutics driven by Unmet Medical Needs” Speaker: Xiaodong Yang, M.D., President, CEO and Member of Board, Apexigen Date and Time: Tuesday, Feb. 28, 2012, 8:30- 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Park in Street and in NOVA and library parking lots across the street.02/28/2012 - 8:30am

Topic Description In the current economic, financial and regulatory environment, it has become increasingly challenging to develop innovative biotherapeutics such as novel antibody-based therapeutics. Apexigen is a start-up biopharma company focusing on discovery and development of best-in-class antibody therapeutics for the treatment of cancer and inflammation. At Apexigen, we believe innovation in drug discovery and development must be driven by the needs of patients. This presentation will illustrate and discuss the opportunities and hurdles facing biopharma companies in growing their businesses and achieving the ultimate goal of delivering innovative medicines to patients.

Speaker Bio Dr. Xiaodong Yang is President and Chief Executive Officer of Apexigen which is a biopharma company focusing on development of antibody therapeutics. He has over 15 years of experience in the research and development of antibody and siRNA therapeutics. Prior to joining Apexigen, Dr. Yang was Vice President of Research and Preclinical Development at Intradigm Corporation (now Silence Therapeutics). In this role, he was responsible for overseeing the progress of company’s discovery and preclinical development of RNAi-based therapeutics. Dr. Yang began his career as a founding scientist at Abgenix (now ). He was Senior Director and the head of the Oncology Therapeutic Program Team responsible for setting strategy and managing the company’s oncology portfolio. Dr. Yang was the project team leader for Vectibix® (panitumumab) and played a key role in discovery, development and BLA approval for Vectibix®. He was also in charge of managing the company’s partnerships on a number of therapeutic antibody collaboration programs. He was an American Diabetes Association and Juvenile Diabetes Foundation postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology, and was also trained as a research fellow at Novartis. Dr. Yang received his medical degree from Beijing Medical University and was awarded his doctorate in Immunology from University of Bern in Switzerland. *************************************************************** Bio2Device Group, Tuesday Evening, March 13, 2012

Topic: “Challenges and Tips for Expanding Your Business into China” Speaker: Matt Levy, Sr. Director, International Market Development, Akonni Biosystems Date and Time: Tuesday Evening, March 13, 2012, 6:00-9:00 pm Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins

Topic Description Matt will provide an overview of his experience working and living in China managing a business unit for various life science and diagnostic companies. Some of the topics will include choosing a legal entity, cultural differences, sales and marketing challenges as well as common pitfalls to avoid.

Speaker Bio Matt Levy is a 10-year industry veteran responsible for leading Akonni’s international expansion into new geographic markets. Akonni Biosystems is a startup company focused on developing new molecular diagnostics that have global applications. Prior to joining Akonni, Matt was Director, International Market Development at Luminex Corporation where he successfully launched operations into Asia on behalf of Luminex. He obtained his initial experience operating in Asia while he was at Applied Biosystems (Life Technologies) where he was responsible for managing the Protein & Small Molecule business unit while residing in China. In addition to his international experience, Matt spent several years in the IBM Life Sciences group where he was responsible for developing and commercializing partner based solutions in various fields such as medical imaging, bioinformatics and protein analysis. Matt has a BS, Business Administration and MS, Computer Information Systems & Quantitative Business Methods from California State University, East Bay. In addition, he has a MBA from Carnegie Mellon University with concentrations in Strategy, Finance and Entrepreneurship.